Protox Therapeutics Inc. announced today that preclinical data demonstrating
PRX302's validity as a treatment for prostate cancer and benign prostatic hyperplasia
(BPH) is being presented in a poster session at the 97th Meeting of the American
Association of Cancer Research (AACR), which is being held this week at the
Washington Convention Centre in Washington, D.C.